Trials / Completed
CompletedNCT02394015
Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
Multicenter and Retrospective Observational Study to Analyze the Efficacy and Safety of the Combination With Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to Data Sheet
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 90 (actual)
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario · Academic / Other
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trabectedin and Pegylated Liposomal Doxorubicin | Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014 |
Timeline
- Start date
- 2013-05-06
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2015-03-20
- Last updated
- 2020-03-27
Source: ClinicalTrials.gov record NCT02394015. Inclusion in this directory is not an endorsement.